Biotechnology and the development of food markets: retrospect and prospects by Moschini, Giancarlo
CARD Working Papers CARD Reports and Working Papers
8-2008
Biotechnology and the Development of Food
Markets: Retrospect and Prospects
GianCarlo Moschini
Iowa State University, moschini@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/card_workingpapers
Part of the Agricultural and Resource Economics Commons, Agricultural Economics Commons,
Biotechnology Commons, Industrial Organization Commons, and the Technology and Innovation
Commons
This Article is brought to you for free and open access by the CARD Reports and Working Papers at Iowa State University Digital Repository. It has
been accepted for inclusion in CARD Working Papers by an authorized administrator of Iowa State University Digital Repository. For more
information, please contact digirep@iastate.edu.
Recommended Citation
Moschini, GianCarlo, "Biotechnology and the Development of Food Markets: Retrospect and Prospects" (2008). CARD Working
Papers. 500.
http://lib.dr.iastate.edu/card_workingpapers/500
Biotechnology and the Development of Food Markets: Retrospect and
Prospects
Abstract
Biotechnology has had an important impact on the agricultural and food industries over the last twelve years
by way of fast and extensive adoption of a few genetically modified (GM) crops. This has produced large
efficiency gains, including higher yields and reduced costs of weed and pest control, as well as some
environmental benefits. The expected development of crops with additional agronomic traits, and with output
traits to improve the nutrition and health attributes of food products, holds the potential for even more
pervasive impacts. Full realisation of such promises may require overcoming the constraining effects of
restrictive GM product regulations.
Keywords
biotechnology, genetically modified products, innovation, regulation, research and development
Disciplines
Agricultural and Resource Economics | Agricultural Economics | Biotechnology | Industrial Organization |
Technology and Innovation
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/card_workingpapers/500
 
 
 
 
 
Biotechnology and the Development of Food Markets: 
Retrospect and Prospects 
 
 
GianCarlo Moschini 
 
 
Working Paper 08-WP 477 
August 2008 
 
 
 
 
 
Center for Agricultural and Rural Development 
Iowa State University 
Ames, Iowa 50011-1070 
www.card.iastate.edu 
 
 
 
 
 
 
GianCarlo Moschini is a professor of economics and the Pioneer Hi-Bred International Chair in 
Science and Technology Policy at Iowa State University.  
 
This paper was prepared for presentation at the XIIth Congress of the European Association of 
Agricultural Economists (EAAE) in Ghent, Belgium, August 29, 2008.  
 
The author thanks Brian Wright for helpful comments on an earlier version of the manuscript, Jim 
Register and Bronwyn Frame for valuable conversations on the science of agricultural 
biotechnology, and three EAAE readers for useful remarks. 
 
This paper is available online on the CARD Web site: www.card.iastate.edu. Permission is 
granted to excerpt or quote this information with appropriate attribution to the authors. 
 
Questions or comments about the contents of this paper should be directed to GianCarlo 
Moschini, 583 Heady Hall, Iowa State University, Ames, IA 50011-1070; Ph: (515) 294-5761;  
Fax: (515) 294-6336; E-mail: moschini@iastate.edu. 
 
Iowa State University does not discriminate on the basis of race, color, age, religion, national origin, sexual orientation, 
gender identity, sex, marital status, disability, or status as a U.S. veteran. Inquiries can be directed to the Director of Equal 
Opportunity and Diversity, 3680 Beardshear Hall, (515) 294-7612.  
 
 
 
 
 
 
Abstract 
Biotechnology has had an important impact on the agricultural and food industries 
over the last twelve years by way of fast and extensive adoption of a few genetically 
modified (GM) crops. This has produced large efficiency gains, including higher yields 
and reduced costs of weed and pest control, as well as some environmental benefits. The 
expected development of crops with additional agronomic traits, and with output traits to 
improve the nutrition and health attributes of food products, holds the potential for even 
more pervasive impacts. Full realisation of such promises may require overcoming the 
constraining effects of restrictive GM product regulations.  
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1. Introduction 
Concerns about food procurement have always mattered. The challenge of population 
pressure faced by an environment saturated with hunter-gatherers, catalysed by the changing 
climatic conditions at the end of the last Ice Age, led some people to attempt the cultivation 
of wild cereals in an effort to supplement their traditional sources of food (Cohen, 1977). 
Thus was agriculture born about twelve thousand years ago in the Fertile Crescent, and 
independently in at least five other distant locations over the next few millennia (Bellwood, 
2005). A dwindling supply of large mammalian prey increased the attractiveness of early 
farming activities, and the ensuing Neolithic revolution saw the widespread transition of 
prehistoric humans from nomadic hunting-gathering bands to agriculture-based 
communities relying on a few successful domesticated species of plants and animals. 
Farming encouraged more permanent settlements, allowing the development of increasingly 
complex social structures and the ushering in of earlier civilisations.  
The path from these early days to the modern world eventually saw the gradual 
augmentation of technology in food production, which supported a population expansion 
that is continuing to this day. Some see that as a vicious circle and also lament that ‘…the 
transition from hunting and gathering to farming eventually resulted in more work, lower 
adult stature, worse nutritional condition and heavier disease burdens’ (Diamond, 2002: 700). 
But civilisation has also led to knowledge accumulation, culminating in the industrial 
revolution and the opening up of increasingly new opportunities. The process of selection of 
plant and animal breeds practised by farmers since the early days of agriculture became more 
systematic with the discovery of Mendel’s laws. The genetic improvement of domesticated 
plants and animals, coupled with the introduction and massive usage of chemical inputs, 
yielded impressive productivity gains that, along with mechanisation, transformed developed 
countries’ agriculture in the twentieth century (see, for example, Gardner, 2002) and led to 
the so-called green revolution in many developing countries (Evenson and Gollin, 2003).  
Biotechnology is the most recent manifestation of how new knowledge can be 
brought to bear on humanity’s longstanding problem of food procurement. The term 
‘biotechnology’ here refers to processes and products inherently related to the use of 
recombinant DNA techniques that originated in the 1970s, what some call ‘modern 
biotechnology’ (Zika et al., 2007). The ensuing ability to manipulate directly the genetic 
makeup of living organisms and its expression brought about a knowledge revolution in 
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biology and opened up tantalising research opportunities, from basic science to practical 
applications in many fields. Health care problems provided the initial motivation for 
biotechnology and some early success stories (such as the commercial introduction of 
human insulin produced by genetically modified [GM] bacteria in 1982), and medical and 
biopharmaceutical applications are to this day attracting the largest share of biotechnology 
research and development (R&D) resources. But many other applications of biotechnology 
have emerged, including its use at various stages in the agricultural and food industry. 
In this article I review some aspects and implications of biotechnology product 
adoption in the agro-food sector.1 The predominant current manifestation of biotechnology 
in the agro-food sector is represented by GM or transgenic crops. In 2007, more than 114 
million hectares worldwide were planted with GM varieties. The current contribution of GM 
crops to food supplies, and the potential future expansion of both the extent and the scope 
of biotechnology in agriculture, indeed makes it a ‘global trend’ worthy of consideration. But 
the development of biotechnology and the adoption of GM crops are still facing a number 
of obstacles and unresolved issues. Vigorous opposition by some segments of the public has 
plagued the reception of this technology from the start. Concurrently, we have seen a 
perhaps unprecedented regulatory activism, and the complex environment that is emerging is 
replete with obstacles for current and future GM innovations. This is particularly true for 
Europe. The EU has articulated an ambitious ‘strategy for Europe’ that, in the agro-food 
area, sees biotechnology as key ‘in fighting hunger and malnutrition and feeding an 
increasing human population on the currently cultivated land area, with reduced 
environmental impact’ (European Commission, 2002: 11). Yet the EU has positioned itself 
at one extreme of GM product regulations, developing and implementing restrictive policies 
that undoubtedly constrain the current status and the future potential of biotechnology in 
Europe.  
 
2. Biotechnology and the agro-food sector 
Applications to the agro-food sector represent a small part of modern biotechnology. Even 
within the narrow sectoral focus on agriculture and food, however, the scope of 
                                                 
1 Given the exceedingly broad scope of the matter at hand, I do not attempt a systematic survey. My 
reference to the literature, while striving to be objective, is by necessity selective and unfortunately 
leaves out many relevant contributions.  
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biotechnology is rather broad (Herdt, 2006). GM crops represent the largest segment at 
present. Current (first-generation) GM crops mostly embed agronomic traits such as 
herbicide resistance and insect resistance. Prospective applications include the tackling of 
more complex agronomic traits, such as drought resistance, as well as the expression of 
output traits. The latter include second-generation GM crops engineered to possess desirable 
quality attributes (such as improved nutritional profiles leading to functional food) and third-
generation GM crops that are suitable for novel uses (such as plant-made pharmaceuticals 
and plant-made industrial products). Animal applications are also being pursued and include 
the development of transgenic livestock and fish with various purposes, such as improved 
production traits, the building of genetic disease models, and the production of biomedically 
useful products in the animals’ blood or milk (Wheeler, 2007). 
 
2.1 Current GM crops 
The pioneering efforts of a few companies—with Monsanto showing a remarkable early 
commitment—led to crop varieties embedding traits engineered by recombinant DNA 
methods to be commercialised in 1996.2 From early on, the strategy was to target traits that 
would have high value for the immediate end users (farmers) by pursuing products with 
herbicide resistance (HR) and/or insect resistance attributes. Weed and insect pressure have 
a first-order effect on expected yields, and their control by way of selective herbicides and 
pesticides is very costly. Earlier instances of first-generation GM crops attacked the problem 
by the insertion of a single foreign gene into the DNA of the desired crop. For example, 
Roundup Ready soybean is resistant to post-emergence exposure to the broad-spectrum 
herbicide glyphosate. This resistance was engineered by the insertion of a gene isolated from 
an Agrobacterium strain. Similarly, genes from the soil-dwelling bacterium Bacillus thuringiensis 
were inserted into corn and cotton to induce expression of proteins that are toxic to the 
larvae of certain Lepidopteran insects (such as the European corn borer in maize).3 
Much work with GM crop breeding at present continues to target important 
agronomic traits. Relief from biotic stresses is provided by biotech traits that seek to provide 
                                                 
2 For an engaging account of the road to initial commercialisation, see Charles (2002). For more 
details on the material of this section, see Zika et al. (2007) and references therein. 
 
3  Because insect-resistant GM crops have been engineered so far with genes from Bacillus thuringiensis, 
such crops are hereafter referred to as Bt crops.  
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insect resistance and herbicide resistance. For maize, in addition to resistance to the 
European corn borer noted earlier, a number of Bt varieties that are resistant to the corn 
rootworm (a Coleopteran insect) and a few related insects are currently available. Similarly, in 
cotton a number of traits aim at improved resistance to insects of the so-called budworm-
bollworm complex. A major trend for these main crops is the stacking of GM traits in the 
same plant. Three-trait stacks are now common, and more ambitious ones are on the way.4 
In addition to combining herbicide and insect resistance, these stacks intend to build 
redundancies in GM crop resistance attributes that, among other things, should make the 
emergence of resistant weeds and insects (through the natural process of pest adaptation) 
less likely. Other agronomic traits currently under development include tolerance to abiotic 
stresses, in particular the development of drought-resistant varieties.  
 
2.2 Prospective GM crop applications 
Major crops for which adoption of GM traits is lagging are wheat and rice. Herbicide-
resistant wheat was on its way to commercialisation, but its development was halted by 
Monsanto in 2004 following pressure from the Canadian and US wheat industry (concerned 
about customer rejection in export markets). GM wheat resistant to fungal diseases (such as 
Fusarium) is being actively researched. GM rice varieties resistant to herbicides, abiotic stress 
and/or embedding Bt genes for insect resistance are being developed in the United States 
and China, as well as at the International Rice Research Institute, and commercialisation is 
expected in the near future. Unlike maize and soybean, the products of which are typically 
fed to animals or find their way into food as refined products, wheat and rice are staple 
foods, which, in view of the concerns discussed later, may account for a greater regulatory 
caution and a slower marketing timetable.  
The development of desired traits in GM crops is not limited to the identification 
and insertion of foreign naturally occurring genes. The DNA of interest may be obtained 
from plants of the same species or from closely related plants, leading to cisgenic plants. An 
interesting alternative approach is the in vitro directed evolution of a gene of interest, 
obtained using the gene shuffling technique, which produces a ‘synthetic’ gene with an 
                                                 
4 For example, Monsanto and Dow Agrosciences announced in September 2007 an agreement to 
develop an eight-gene stack for corn varieties, combining resistance to at least two herbicides and to 
a large spectrum of insects.  
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amplified expression of the characteristic of interest. One such example is Dupont’s ‘GAT’ 
technology conferring herbicide resistance in a novel way (glyphosate is actually detoxified in 
the plant).5 Another biotechnology technique that is becoming pivotal in crop improvement 
is marker-assisted breeding, whereby molecular biology techniques complement traditional 
breeding to accelerate the identification and selection of desired traits.  
Future GM traits are expected to address output characteristics by improving the 
nutritional profile of the crop. ‘Functional foods’ with health benefits beyond basic nutrition 
present exciting possibilities for GM crop development (Pew Initiative, 2007). Examples are 
vegetable oils with an improved fatty acid profile, and staple crops with improved content of 
protein, minerals and vitamins. Such GM crops hold considerable potential for 
biofortification as a strategy to improve the nutrition of the poor in developing countries 
(Golden Rice, which embeds genes that improve the content of beta-carotene, the precursor 
of vitamin A, is a well-known example). Other crop biofortification projects include GM 
potato with higher protein content, as well as GM cassava and GM sorghum with a wide 
array of improved nutritional characteristics (Pray et al., 2007). Other future applications 
concern molecular farming whereby GM crops can be used to produce plant-made 
pharmaceuticals (e.g., monoclonal antibodies and vaccines) and plant-made industrial 
products (Moschini, 2006). Of current interest is the prospect of developing GM crops 
specifically designed for biomass yield for use in biofuel production.  
 
2.3 Concerns about GM crops 
Surveys of public attitudes routinely find that a sizeable segment of the population holds 
misgivings and reservations about biotechnology, and that this is particularly the case for 
agricultural and food applications of biotechnology (e.g., Gaskell et al., 2006). A variety of 
concerns to explain such an opposition to GM crops have been articulated, including (a) fear 
that intake of GM-based food products may be harmful to humans (e.g., the introduction of 
novel allergens), (b) concern that production of GM crops may be harmful for the 
environment (through gene flow, resistance build-up and biodiversity impacts), (c) ethical 
considerations, possibly predicated on religious views, and, (d) the role of patents and the 
proprietary interests of multinational corporations. 
                                                 
5 Soybean and maize varieties with the GAT gene are expected to be marketed as early as 2009.  
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The intellectual root of safety concerns about GM crops can be traced back to the 
reservations and debate that greeted recombinant DNA technology immediately after its 
introduction, leading to a temporary voluntary moratorium on its use, the celebrated 1975 
Asilomar conference, and subsequent guidelines and regulations by the US National 
Institutes of Health. Twenty years later—and, interestingly, on the eve of the release of 
commercial GM crops—all of the earlier serious concerns appeared to have been dispelled, 
at least to the satisfaction of scientists (Berg and Singer, 1995). In short, the evidence 
showed that millions of experiments had been carried out without incidents or documented 
hazards to public health. The paradigm-changing advent of recombinant DNA research had 
delivered much in terms of increasing knowledge of fundamental life processes, had already 
led to some useful products (for example, human insulin), and promised much for the 
future.  
That this upbeat take-home message has been less than universally accepted in the 
GM food debate that followed certainly reflects, among other things, the difficulties of a 
rational public discourse on matters of sophisticated science that involve actors with vastly 
heterogeneous scientific literacy. Still, it is obviously impossible to claim the absence of any 
risk in this context. That biotechnology innovations may entail risks is thus possible, as one 
should expect with other technologies that are novel in some fundamental way, and for 
which some degree of uncertainty is inevitable. Some of these earlier apprehensions with 
GM crops were certainly legitimate. But, as with most such concerns, what is needed is more 
scientific knowledge (rather than an ideological reckoning). 
A strong scientific consensus is emerging that GM technology itself poses no 
inherent risk for human health. The International Council for Science provided a careful, 
comprehensive assessment of this matter and concluded that ‘there is no evidence of any ill 
effects from the consumption of foods containing genetically modified ingredients’ (ICSU, 
2003: 8). The conclusion that current GM products are as safe to eat as their conventional 
counterparts is the official opinion of a number of national science academies and the 
official position of several intergovernmental agencies, including the Codex Alimentarius 
Commission on food safety (a joint undertaking of the Food and Agriculture Organisation 
and the World Health Organisation). Indeed, some clearly positive effects are evident as 
well. For example, Bt maize shows reduced incidence of some mycotoxins (such as 
fumonisin) that may cause serious health problems in animals and humans.   
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As for the environmental effects of GM crops, it is important to stress that the 
practice of agriculture inevitably affects the environment. That has been true since the early 
days, and it is certainly the case for the modern agricultural practices (with or without GM 
crops). In any event, a careful assessment of the vast scientific evidence accumulated over 
the last decade from field research and commercial cultivation has uncovered no evidence 
that GM crops have caused significant environmental harm. In fact, a number of positive 
environmental effects have been documented (e.g., Sanvido et al., 2006). Bt crops, 
particularly cotton, have led to a decrease in pesticide used for insect control, and adoption 
of HR crops has resulted in a favourable change in the composition of applied herbicides 
towards glyphosate, a herbicide that is considerably more benign (lower toxicity and lower 
persistence) than alternative, more selective herbicides that the GM crop practice replaces. 
Evidence from cotton cultivation in China, and from GM rice preproduction trials, has also 
shown another highly valuable impact from the induced reduction in the use of certain 
insecticides, namely, improved farmers’ health (Huang et al., 2005). Cultivation of HR crops 
can also promote the use of reduced tillage practices, thereby reducing soil erosion.  
 
3. Adoption and economic impacts of current GM crops 
The GM crop technology has been extremely successful, by the historical standards of 
previous agricultural innovations. Only twelve years after their introduction, in 2007 GM 
crop varieties accounted for more than 114 million hectares worldwide (Table 1). Production 
is, however, highly concentrated: just three countries (Unites States, Brazil and Argentina) 
accounted for about 80 per cent of that area in 2007. Commercialised GM traits are also 
limited to a few main commodities. In 2007, virtually the entire GM area was taken by four 
crops with the following shares: soybean, 51.3 per cent; maize, 30.8 per cent; cotton, 13.1 
per cent; and canola, 4.8 per cent. For countries that have led the adoption of GM crops, the 
market penetration (relative to traditional varieties) is remarkable. For example, in the United 
States, the country with the largest adoption to date, the share of land allocated to GM 
varieties in 2007 was 91 per cent for soybean, 73 per cent for maize and 87 per cent for 
cotton (NASS, 2007). From Table 1 it is evident that Europe is essentially absent from this 
picture; in 2007, only an estimated 110 thousand hectares of GM crops were grown in the 
EU—involving just one event (MON810) in just one crop (maize) grown mostly in one 
country (Spain) (GM varieties accounted for about 1 per cent of the EU maize planted area). 
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From an economic perspective, the first generation of GM crops increase expected 
yields and/or reduce the cost of weed and pest control (including cost savings made possible 
by the induced simplification of some crop management activities), as well as reducing the 
quantity of insecticides used to control insect populations (Fernandez-Cornejo and Caswell, 
2006). The revealed preference of enthusiastic farmers’ adoption choices, despite the price 
premium that GM varieties typically command, clearly attests to such efficiency gains. The 
yield gains due to Bt varieties, particularly in cotton, have been impressive, especially in 
developing countries (Qaim and Zilberman, 2003). Thus, GM crops enhance production 
efficiency, very much as did traditional agricultural research whose innovative products 
transformed twentieth century agriculture. In addition, as noted earlier, the reduced use of 
pesticides and the change in the composition of herbicide used brought about by GM crops 
translate into substantial positive environmental benefits. 
One feature that distinguishes GM crops is that their development and 
commercialisation firmly belonged in the private sector,6 whereas earlier agricultural 
productivity gains owed much to public sector research (Huffman and Evenson, 1993). For 
crop breeders, the solution of the classical problem of how firms can profit from 
technological innovation (Teece, 1986) benefited from a changing landscape for intellectual 
property rights (IPRs). In the United States, the strengthening of IPRs that followed the 
1982 establishment of a centralised appellate court for all patent cases was, for 
biotechnology innovations, compounded with the effects of the landmark 1980 Supreme 
Court decision of Diamond v. Chakrakarty that greatly expanded the scope of patenting in the 
life sciences. The recent strengthening of IPRs is a trend observed internationally as well, 
although important differences for the protection of agriculture-related innovations remain 
(Moschini, 2004). 
The early enthusiasm for the life sciences company model has waned somewhat, but 
the burst of acquisitions, spin-offs and mergers that followed completely redesigned the seed 
and agro-chemical industries of developed countries, with an increased consolidation and a 
central role for intellectual property over both GM traits and germplasm (Wright and Pardey, 
                                                 
6 A notable exception is GM papaya resistant to the ringspot virus, developed thanks to the efforts of 
researchers at Cornell University and at the University of Hawaii at Manoa. Papaya ringspot virus had 
nearly destroyed papaya production in Hawaii by the time GM varieties of papaya became 
commercially available in 1998, literally saving the industry.  
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2006).7 The concentration of the seed and agro-chemical industries and the critical role of 
proprietary technologies are a common source of concern (see, for example, UNCTAD, 
2006). Although concentration per se does not imply negative welfare effects, a number of 
open questions in this area need further study. When innovation is central, however, welfare 
considerations ought to include the ex ante perspective of what incentives are suitable to 
bring forth desired research efforts. IPRs are crucial for private R&D investments in fields 
(such as biotechnology) in which innovations are easily copied (a predicament that actually 
applies to traditional germplasm as well). If private R&D is to be relied upon for major 
agricultural biotechnology innovations, as the global trend to a diminished role of public 
support for agricultural research suggests, the privatisation of some critical research output 
may be inevitable.  
Assessing the net economic value of efficiency-enhancing innovations is typically 
done by estimating the associated changes in producer and consumer surpluses in a partial 
equilibrium setting (Alston et al., 1995). But because of the proprietary nature of GM 
innovations, there is a need to account for market power in the quantitative evaluation of the 
welfare impact of innovation adoption (Moschini and Lapan, 1997). Earlier studies that 
accounted for this issue documented sizeable efficiency gains from new GM crops (Falck-
Zepeda et al., 2000; Moschini et al., 2000) and showed that these economic benefits were 
shared by farmers, innovators and consumers.8 In particular, with reference to the market 
power and IPR issues discussed earlier, it was found that agro-biotechnology innovators 
typically capture only a fraction of the ex post benefits of GM innovations. These studies, in 
any case, did not attempt to include the possible externality effects of GM crops. As noted 
earlier, the evidence to date points to a net positive environmental impact of GM crops. 
Thus, explicit accounting of such external effects (the quantitative evaluation of which is 
clearly a difficult task) would reinforce the foregoing results concerning the positive welfare 
impacts of GM crops.  
 
 
                                                 
7 Monsanto, for example, underwent a remarkable transformation from an agro-chemical concern 
without any seed business to the largest seed company in the world. 
 
8 For example, the welfare gains from worldwide adoption of HR soybeans were estimated by 
Moschini et al. (2000) to exceed $2 billion per year, with innovators capturing 37 per cent of that, 
farmers receiving 22 per cent, and consumers claiming 41 per cent. 
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3.1. The product differentiation hypothesis 
The conclusions of the foregoing studies are predicated upon the assumption that the new 
GM crops are merely more efficient but otherwise equivalent to traditional varieties. This 
assumption is seemingly at odds with the observation of opposition by some segments of 
the public, suggesting a degree of consumer resistance to the new GM crops. Taking such a 
hypothesis at face value implies that, from a consumer perspective, food products 
manufactured with the new GM crops are only imperfect substitutes for the corresponding 
conventional products—indeed, they provide an inferior quality relative to traditional foods 
in the vertical product differentiation (VPD) sense (see Mussa and Rosen, 1978). The fact 
that GM food is thus a ‘weakly inferior’ substitute for conventional food affects the potential 
welfare impact in at least two ways. First, it implies a smaller potential market for the new 
GM products. Second, and more subtly, to deliver traditional GM-free food in the post-GM 
world, additional costs must be incurred (relative to the pre-innovation situation). That is, 
costly (and hitherto unnecessary) segregation and identity preservation activities are required 
if the two types of food (GM and non-GM) are to be differentiated in the market. The GM 
innovation process, therefore, has also introduced a new market failure, a type of externality 
on the production of traditional food products (Lapan and Moschini, 2004).   
Models that account for such VPD consumer preferences, and the need for 
segregation and identity preservation to achieve the desired product differentiation between 
GM and non-GM products, have found that the welfare implications of introducing first-
generation GM crops can be ambiguous (Fulton and Giannakas, 2004; Lapan and Moschini, 
2004; Lence and Hayes, 2005; Sobolevsky et al., 2005). This situation is not a standard 
aggregate externality in the sense that, to a first approximation, the negative impacts of GM 
crop adoption depend on the fact that some GM crops are being grown at all, and less so on 
the extent of GM crop cultivation.9 Put another way, this external effect essentially induces a 
nonconvexity in the aggregate production set. Given this external effect, one can no longer 
presume that the competitive equilibrium achieves Pareto efficiency, which provides grounds 
for policy intervention. But if the nonconvexity argument is the crux, what might be called 
for is a ban on the new technology rather than policies that affect adoption at the margin. 
                                                 
9 Bullock and Desquilbet (2002) find that a major resource cost of segregation and identity 
preservation is due to the flexibility loss of having to move from one to two handling channels (one 
for GM products and one for non-GM products). 
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That is, having approved a given GM product, it may be desirable to have a larger rather 
than smaller diffusion. In particular, disincentives to the (marginal) adoption of GM 
products (as might be the case for some EU coexistence measures discussed later) decrease 
aggregate welfare (see Moschini et al., 2005). In any event, the conclusion that otherwise 
efficiency-enhancing innovations might have detrimental net welfare effects depends 
critically on the extent of consumers’ aversion to GM products, a question that is discussed 
next. 
 
3.2. Assessing consumer response to GM food 
To what extent are GM products weakly inferior from the consumers’ viewpoint? The 
foregoing market studies do not provide an independent quantitative assessment of this 
effect; they simply assume that it might exist and calibrate parametric scenarios to illustrate 
possible impacts. To estimate consumers’ actual differential valuation of (otherwise 
equivalent) GM and non-GM products, ideally one would want to rely on observed 
consumer behaviour in a real market setting. That not being typically possible, economists 
have borrowed from valuation techniques used in environmental economics (contingent 
valuation and experimental methods) to assess consumers’ willingness to pay (WTP) for the 
non-GM attribute. Despite the sheer volume of work accumulated to date, however, it is 
difficult to decide just what we know about the question of interest. 
 Contingent valuation (stated preference) suffers from well-known drawbacks, the 
foremost one perhaps being its ‘hypothetical bias’ whereby the lack of real economic 
commitment to a transaction inflates stated WTP values (Neill et al., 1994). Experimental 
methods have the potential to improve on that, and their use has become quite popular to 
assess consumers’ preferences vis-à-vis GM and non-GM products. Often this takes the form 
of an experimental auction setting where subjects bid for the possibility to exchange a GM 
item (such as a chocolate-chip cookie or a bag of potato chips) for the corresponding non-
GM good, leading to a direct elicitation of the subjects’ WTP. Alternatively, subjects can 
exchange a given non-GM item for the corresponding GM good, leading to the elicitation of 
a willingness to accept (WTA) value. Lusk et al. (2005) summarise the results from 25 such 
earlier studies (providing 57 valuations) and find non-negligible premia for non-GM foods 
(e.g., the simple average of the non-GM premium over all observations, but excluding one 
clear outlier, was found to be 29 per cent). But much variability is found in these GM 
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valuation results, and even within a single study considerable heterogeneity exists. For 
example, Noussair et al. (2004) found that, even for French consumers (who, according to 
consumer-attitude studies, are notoriously anti-GM), about one-quarter of them are 
indifferent and about two-thirds are willing to buy GM products at some price.  
 Although the revealed-preference nature of experimental methods might be more 
appealing than the stated preference of contingent valuation surveys, exactly how one can 
translate such results to the market remains an open question. As Levitt and List (2007: 170) 
put it, ‘Perhaps the most fundamental question in experimental economics is whether 
findings from the lab are likely to provide reliable inferences outside of the laboratory’. In 
some instances (as, for example, when the experiment is serving a methodological purpose, 
such as comparing different game-theoretic solution concepts), this ‘generalisability’ issue 
may not be important. But when, as in our case, the object of interest concerns a quantitative 
assessment of the consumers’ expected buying behaviour for GM products, generalisability 
is critical, and a number of considerations suggest that the existing applied studies may not 
provide reliable enough estimates. For example, the large difference between WTP and 
WTA measures found in existing studies, documented in Lusk et al. (2005), is difficult to 
rationalise for a setting that, by construction, should have an income effect that is essentially 
nil.10 Also problematic is the finding that subjects are willing to pay large private amounts for 
what is essentially a public good (e.g., environmental benefits) (Lusk et al., 2004).11 
 The value of the non-GM attribute elicited for a given subject in a given experiment, 
in addition to being highly sensitive to the particular experimental setting, likely reflects the 
idiosyncratic nature of the information possessed by the subject. Rousu et al. (2007) find that 
information (both for and against GM) can be critical in shaping the subjects’ WTP for non-
GM. In addition to establishing that verifiable information provided by third parties might 
improve welfare, as noted by the authors, this finding also suggests that extrapolating 
experimental results to a market setting—where consumers’ information is continuously 
                                                 
10  Because a large divergence between WTP and WTA is common, WTA is usually avoided in 
contingent valuation studies. Harrison (2006) calls this situation embarrassing and suggests that best-
practice experimental methods should be able to improve on that. 
 
11 In fact, Noussair et al. (2004) postulated that one reason their experimental results did not match 
the more negative picture arising from consumer attitude surveys was precisely that the latter are 
likely to elicit a response that includes consumers’ assessment of the externality, whereas bidding 
behaviour in an experiment likely focuses on the private value of the object (as standard theory 
would imply). 
 13
updated and where consumers’ habit formation may lead to considerable divergence 
between immediate and long-run behaviour—may indeed be tricky. The role of information 
is also stressed by Knight et al. (2007), whose marketing study carried out in seven countries 
suggests that GM products may be more acceptable than reported in previous studies.  
The possibility that consumer attitude studies and experimental studies might in fact 
provide limited guidance as to actual consumers’ purchasing behaviour vis-à-vis GM products 
is also stressed by Kalaitzandonakes et al. (2005). Using scanner data on actual purchases, 
they find that consumers in the Netherlands did not alter their shopping choices for a period 
(1997-2000) in which some GM-labelled products were actually labelled along with 
corresponding non-GM goods. Indirect corroborating evidence is offered by the US 
experience with the use of recombinant bovine somatotropin (rbST) in milk production. 
Considerable controversy surrounded the approval process and introduction of this 
technology in 1994. Pre-commercialisation surveys documented widespread concerns about 
safety, leading to predictions of a sizeable drop in milk demand following the introduction of 
rbST. Such predictions turned out to be incorrect, however, as the evidence shows that the 
(unlabelled) introduction of rbST did not affect actual milk purchasing decisions (Aldrich 
and Blisard, 1998).  
The presumption that consumer demand might be significantly affected by first-
generation GM products clearly needs further scrutiny. The possibility that consumers’ 
unfettered preferences can be revealed through market transactions, however, is heavily 
constrained by many features of existing GM regulations. 
 
4. The regulation of GM crops 
GM crops and their products are subject to a host of national regulations around the world. 
The United States, with its 1986 Coordinated Framework for Regulation of Biotechnology, 
chose to rely on pre-existing laws and federal agencies (Pew Initiative, 2004). The stated 
overriding principle is that the use of biotechnology is not risky per se, so that it is not the 
‘process’ but rather the ‘product’ that should be the object of interest. Still, the USDA 
presumption is that GM plants might be plant pests, so that they are considered ‘regulated 
articles’ and require authorisation for environmental release (for example, field tests). Upon 
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successful experimental release, a GM crop can obtain non-regulated status,12 after which it 
can be freely commercialised without further specific oversight. In the deregulation process, 
a substantial amount of information on the food and environmental safety of a GM crop is 
developed and shared with regulators. The US Food and Drug Administration (FDA) does 
not require premarket approval for food that is ‘generally recognised as safe’ (GRAS), a 
determination that is the responsibility of the party putting the product on the market. 
Because food produced from (first-generation) GM crops is deemed substantially equivalent 
to conventional food, the GRAS status essentially follows. Nonetheless, GM crop 
developers have, in all cases to date, submitted detailed safety and nutritional assessments to 
FDA scientists under a voluntary consultation procedure. 
The EU views GM crops and products as fundamentally novel and in need of an ad 
hoc regulatory structure. The earlier process of GM crops approval was put on hold in 1998 
with a de facto moratorium that led, among other things, to a World Trade Organisation 
(WTO) dispute brought by the United States, Canada and Argentina.13 The new regulatory 
framework developed since then, which became fully operational in 2004, is rather complex: 
it draws upon a number of directives and regulations and it involves decision roles for both 
national authorities and EU-level bodies (European Union, 2006). The main instrument is 
Regulation (EC) No 1829/2003, which provides for a single procedure (the one door, one 
key principle) for new authorisations of GM food and feed in the EU. A single risk 
assessment process is envisioned, under the aegis of the European Food Safety Authority 
(EFSA), which is responsible for the scientific assessment of both environmental risk and 
(human and animal) health risk. Next, for the risk management stage, based on the opinion 
of EFSA, the European Commission makes a proposal on the granting or refusal of the 
authorisation, which must be approved by member states (through a standing committee 
operating under the qualified majority rules). If member states fail to agree, the matter is 
referred to the Council of Ministers and, upon failure to resolve the impasse, the 
Commission has a final decision opportunity. 
                                                 
12 Only for plants modified to express pharmaceutical or industrial traits is no deregulation 
envisioned at present. 
 
13  The final WTO ruling, published in September 2006, essentially upheld the central claims against 
the EU, although the implications of these findings turned out to be moot in light of the recent 
overhaul of EU policies and procedures dealing with GM crop approvals. 
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The differences between the US and EU approval processes are perhaps most 
evident at the risk management stage, where the EU displays a deeper and more complex 
political oversight. But the EU also implements two major types of post-market regulations: 
mandatory GM labelling and coexistence measures. Since April 2004, products consisting of 
or containing GM organisms and food products obtained from GM organisms are subject to 
mandatory labelling and traceability requirements as established in Regulation (EC) 
1830/2003 (European Union, 2006).14 These labelling rules also apply to animal feed. To 
avoid the GM label, the content of (authorised) GM product must not exceed 0.9 per cent, 
provided the presence of this material is adventitious or technically unavoidable. Traceability 
is a general requirement under the EU General Food Law 178/2002, but Regulation (EC) 
1830/2003 sets out more specific and onerous requirements for GM products. Coexistence 
is articulated in Recommendation 2003/556/EC, which provides ‘guidelines for the 
development of national strategies and best practices to ensure the coexistence of genetically 
modified crops with conventional and organic farming’ (European Commission, 2003: 36). 
The main concern is adventitious contamination at the farm level as may arise from using 
impure seed lots,15 cross-pollination and sharing of harvesting machinery. Measures 
contemplated include spatial isolation (such as mandatory isolation distances between GM 
and non-GM plots, use of buffer strips) and time isolation (JRC-IPTS, 2006). The stated 
intention of coexistence measures is to address economic and marketing implications, not 
safety issues (which are assumed to have been dealt with at the approval stage).  
Many countries have or are introducing their own GM product regulations with 
measures that fall within the spectrum of options delineated by the US and EU approaches. 
Harmonisation of such measures is proving a challenging undertaking, as several 
international bodies claim some say in the matter. The Codex Alimentarius is a commission 
charged with developing standards for food safety. These standards are voluntary, although 
they provide the usual benchmark for national policies and for the WTO. But the GM food 
issue is proving unyielding for the Codex, and no conclusive guidance is emerging. The WTO 
itself has a stake in preventing the misuse of national regulations as nontariff barriers to 
                                                 
14 Such items must carry a label stating something like ‘This product contains genetically modified 
organisms’. Products such as meat or milk obtained from animals fed with genetically modified feed 
are exempt. 
 
15 An unresolved issue, in this context, is that no specific tolerance level for the adventitious co-
mingling of non-GM seed has been agreed upon. 
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trade.16 The still unfinished case brought against the EU policies in 2003, which did not 
pertain to the newer mandatory labelling and coexistence measures, may yet give way to a 
broader challenge. In this respect, the implications of the EU regulatory policies spill over its 
own borders, as exporting countries are wary of the impact their GM-related actions can 
have on access to the EU market. 
 
4.1. Are GM products overregulated? 
As the foregoing review illustrates, GM crops typically must undergo pre-market evaluations 
and approvals that traditionally bred crop varieties can eschew. But the prevailing scientific 
view on this matter is that the use of recombinant DNA techniques in crop breeding does 
not, per se, produce more risky crops (see, for example, Bradford et al., 2005). New 
biotechnology techniques might actually provide a higher degree of control of DNA 
manipulations that have always been part and parcel of crop breeding. This scientific 
viewpoint argues that it is illogical to subject GM crops to a much higher degree of scrutiny 
than traditionally-bred crops because the use of gene splicing does not entail any unique risk 
(Miller and Conko, 2004). That is, from the perspective of human or environmental risk, it is 
not the process but rather the product that matters. This perspective on risk regulation calls 
for proportionality of measures with the objective risk at hand, and for consistency 
(McHughen, 2007). Such consistency often appears to be missing when it comes to GM 
crop regulation. For example, mutation breeding—whereby random mutations in a plant’s 
genome are induced by such disruptive techniques as irradiation—is typically accepted as less 
risky than gene splicing and in need of none of the scrutiny required of GM crops.17  
 Insofar as the current regulatory structure leads to equivalent hazards being treated 
very differently, negative welfare consequences obviously follow. In particular, singling out 
certain new products for undue regulation can distort incentives for R&D and affect the 
flow of innovation, with negative welfare effects in the long run. In the case of GM crops, 
there is some evidence that regulatory compliance costs are very high (Kalaitzandonakes et 
                                                 
16 The Cartagena Protocol on Biosafety, drafted in the context of the UN Convention on Biological 
Diversity, also claims influence on the transboundary movement of GM products (therein labelled 
living modified organisms) intended for environmental release. 
 
17  Also known as mutagenesis, this technique has been used to develop more than 2,200 
commercialised plant varieties (Bradford et al., 2005). Mutagenesis is explicitly exempt from the EU 
regulation of GM products. 
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al., 2007). The high cost of regulatory approval, in particular, might make it prohibitive for 
small firms and public research labs (like universities) to bring new varieties to market, which 
might skew the portfolio of commercially available varieties in favour of large seed 
companies (and thus contribute to the sort of industry consolidation, referred to earlier, that 
gives rise to concern). 
 
4.2. What is a sensible GM labelling policy?  
A number of countries have introduced or are considering GM labelling requirements 
(Gruère and Rao, 2007), but the sweeping attributes of the EU labelling rules stand out. 
Their mandatory nature, in particular, is in sharp contrast with the regulatory approach 
pursued in Canada and the United States, where at most a voluntary GM labelling system is 
envisioned.18 Given the presumption that pre-approval risk assessment and management 
allows only safe GM products on the market, from an economics perspective the remaining 
role for labelling is that of allowing a successful product differentiation (vis-à-vis the GM and 
non-GM attributes) for the benefit of the consumer. Thus, labelling deals with the 
asymmetric information problem that might lead to the market failure originally described by 
Akerlof (1970).  
The crucial question is whether labelling should be voluntary and pertain to a 
perceived positive attribute (i.e., non-GM) or mandatory for the presumed negative attribute 
(GM). Both labelling systems can convey the same information to consumers. A coherent 
labelling policy, however, must consider that the relevant information of interest to the 
consumer (i.e., the non-GM nature of the superior product) here needs to be produced by 
costly segregation, identity preservation and systematic testing, and that it is the providers of 
the non-GM product who have the best incentives to undertake such activities effectively 
(Moschini and Lapan, 2006). The standard conclusion, therefore, is that voluntary labelling 
of the non-GM attribute is preferable from an economics perspective (e.g., Golan et al., 
2001). Indeed, the cases of organic food and of kosher food provide two excellent examples 
of successful voluntary labelling programs in similar settings.  
                                                 
18 Also, the threshold level to avoid labelling (0.9 per cent) is very strict when compared with the 
purity levels for GM labelling used by other countries (e.g., South Korea and Japan use a 3 per cent 
and a 5 per cent threshold, respectively). Lapan and Moschini (2007) relate the determination of a 
purity level for the purpose of GM labelling to the theory of grading and minimum quality standards 
in an explicit model with VPD preferences. 
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A problem with mandatory GM labelling is its justification by appeal to the 
consumers’ ‘right to know’, a motivation explicitly underlying the EU approach. Such a 
generic right-to-know is too open-ended and potentially unbounded (it can be invoked for 
virtually anything), and it does not compare favourably to the more compelling ‘need to 
know’ rationale when viewed in the context of risk communication. In fact, labels are also 
routinely used, and often mandated, to warn consumers of specific hazards (e.g., warning 
labels on cigarettes). Viscusi (1998: 28) notes that mandating information disclosure through 
labelling gives ‘policymakers an intermediate policy option when there is insufficient 
evidence to warrant direct regulation, but enough concern about the potential risk to alert 
the public of the need for care’. The variety of opinions expounded in the popular media on 
the safety of GM food could, given the level of scientific literacy of the typical consumer, 
lead the public to infer that if authorities require the labelling of GM food, then there might 
indeed be a risk in consuming it. Hence, the stigmatising effect of mandatory labelling of 
GM food is itself bound to affect consumer perception of risk and make food retailers wary 
of carrying and selling GM food.  
 One specific aspect of the EU labelling rules that is questionable relates to the need 
to label GM foods regardless of whether or not DNA or proteins derived from genetic 
modification are contained in the final product (so that the GM labelling requirement also 
pertains to highly refined products, such as vegetable oil). At the same time, the rules 
distinguish between such products, held to be produced ‘from’ a GM source, and something 
produced ‘with’ the aid of a GM product, which need not be labelled. This subtle distinction 
turns out to be rather important because it exempts cheese, when produced with chymosin 
obtained from GM microorganisms, from having to carry a GM label.19 
 
4.3. The problem of coexistence 
One of the stated principles of the EU recommendations on coexistence is that farmers 
‘who introduce the new production type should bear the responsibility of implementing the 
farm management measures necessary to limit gene flow’ (European Commission, 2003: 41). 
This clearly envisions a strong assignment of property rights. On the one hand, such clarity 
                                                 
19 Traditionally obtained as rennet (rendered from the stomach of milk-fed calves), chymosin is an 
enzyme essential in cheese production that can now be produced from GM bacteria or yeast. In the 
EU, chymosin was the first enzyme from a GM source to be approved for use in food preparation, 
and it is now widely used in cheese production. 
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might be welcomed, as the bilateral externality that measures such as buffer strips and 
isolation distances are meant to address falls within the scope of the celebrated Coase 
theorem (Beckmann and Wesseler, 2007). Specifically, costless bargaining between GM 
adopters and non-adopters should lead to an efficient allocation of land, involving strong 
regional agglomeration of GM and non-GM production areas, regardless of the particular 
assignment of property rights. In practice, however, transaction costs and informational 
asymmetries are likely to make that argument moot, and putting the onus of farm-level 
coexistence on GM farmers alone is likely to negatively impact GM adoption. Some of the 
proposed rules are extremely restrictive and arguably prohibitive for prospective GM crops 
adopters (Demont et al., 2008). In particular, strict local ex ante regulations invoked under the 
notion of coexistence, at times including the need for prior approval for GM plots, and 
uncertainty about the implied potential liability issues may provide strong deterrence to 
farmers’ adoption of GM crops (Beckmann et al., 2006).  
A simpler (arguably more market-oriented) alternative for coexistence would place 
on non-GM producers the onus of ensuring adequate purity (as defined by GM labelling) of 
the non-GM product. Given the heterogeneity of production conditions, and the stochastic 
nature of the potential contamination problem that coexistence measures intend to prevent, 
a non-GM farmer may be the best positioned to determine what measures are necessary to 
meet the target purity level. One should also re-emphasise that coexistence measures are not 
meant to keep risky products out of the market (an issue for the GM product approval 
stage), but are best viewed in the context of the induced product differentiation hypothesis. 
Preventing contamination at the farm level is only one step in a marketing and processing 
chain that needs to rely on segregation and identity preservation activities if a credible non-
GM product, in an environment where both GM and non-GM crops are grown, is to be 
delivered to consumers. Throughout that chain, the incentive for efficient diligence rests 
with the operators that pursue the marketing of the (superior) non-GM product, and thus it 
seems desirable to align the incentives at the farm level with those of the entire supply chain. 
 
5. Some current issues 
The current regulation of GM crops, including some associated policy uncertainty, appears 
to be a major factor for the future development and adoption of GM products and bears 
heavily on how biotechnology will affect the development of food markets. In Europe, in 
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particular, the climate remains unfriendly to GM products. Much has been written to explain 
the roots of that hostility (see, for example, Scholderer, 2005), with considerations ranging 
from the lingering impact of some food safety scandals (such as the bovine spongiform 
encephalopathy crisis), exacerbating a low public confidence in food safety authorities, to a 
culturally ingrained scepticism towards science, which some relate to the adoption of the 
‘precautionary principle’ for risk regulation. Other possible explanations might point to 
political economy arguments, including old-fashioned trade protectionism (Lapan and 
Moschini, 2004) as well as the desire to protect the interests of established European agro-
chemical firms heavily invested in traditional crop-protection technologies (Anderson and 
Jackson, 2006; Graff and Zilberman, 2007).  
Appeals to the precautionary principle to rationalise European GM policies, in 
particular, need further scrutiny. From a positive perspective, in a broader context, there is 
no evidence that risk regulations in Europe are systematically more risk-averse and 
precautionary than those of the United States (Hammitt et al., 2005). From a normative 
perspective, the economics of the precautionary principle emphasises rational decision 
making in the face of uncertainty, risk and the possibility of learning, and a variety of 
prescriptions for action (some of which are in stark contrast with each other) are possible, 
depending on how one frames the decision problem (e.g., Gollier, 2001; Hennessy and 
Moschini, 2006). The choice between the newer technology of GM crops and otherwise 
modern (chemically dependent) agricultural practices with traditional varieties cannot be 
construed as a choice between a ‘risky’ alternative and a ‘safe’ one. There are risks associated 
with adopting GM crops, just as there are risks in rejecting them, and the real question 
should concern the balance of the perceived benefits and risk tradeoffs (Zilberman, 2006).  
Leaving aside the structure of GM regulation, the timeliness of its implementation 
matters as well. In the three years since resuming GM trait approval in 2004, only nine new 
events have been approved in the EU (more than 30 are lingering in the pipeline), of which 
none is for actual cultivation (USDA, 2007).20 Furthermore, a number of member states 
continue to implement GM product bans that conflict with the EU’s own approved 
products. One implication of the EU reluctance to implement its own GM rules is the 
                                                 
20 For all these cases, a qualified majority of the member states did not materialise, despite a positive 
risk assessment of the EFSA, and the Council did not make a decision, so that in the end these 
authorisations were granted by the Commission itself. 
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growing divide that is emerging between approved GM traits in the EU vis-à-vis approved 
traits in other major producing and exporting countries. For example, as of March 2008, 14 
of 24 traits or trait-stacks being commercialised in US maize seed for the 2008 growing 
season do not have either EU food or feed approval (10 out of 24 have neither) (US 
National Corn Growers Association). This situation of ‘asynchronous’ GM trait approvals, 
coupled with the effective zero tolerance on unapproved traits envisioned by the current EU 
regulations, is putting considerable stress on EU imports of feed products. The trend for 
these asynchronous approvals is not promising, as major producing areas outside the United 
States are also poised for widespread adoption of stacked-gene GM varieties, most of which 
are still unapproved in the EU. All this contributes to higher feed and food prices, and to a 
loss of competitiveness for the EU livestock industry, as the Commission’s own study 
recently articulated (European Commission, 2007).21 
 In addition to the implications of the process of GM trait approval just discussed, 
post-market regulations of GM products are having a direct effect on EU food markets. In 
short, essentially no labelled GM product is to be found in European grocery stores. Retail 
chains are particularly leery of being singled out by anti-GM activists. The relevance of 
private labels in the retailing strategy of major firms heightens the risks of a possible brand 
tarnishing. Given this, it appears that the food industry has responded to the overarching 
GM regulatory structure by developing supply chains that simply exclude GM products (and 
often implement private procurement standards that are tighter than those mandated by 
current regulation). The strategic equilibrium in the food industry thus engineered is scarcely 
different from a collusive outcome. In the end, the mandatory labelling of GM products 
implemented by the EU seems to achieve the opposite of its purported objective: instead of 
providing consumers with a meaningful right to choose, it is tantamount to a de facto ban 
on retailing of GM products. Similarly, the restrictive coexistence rules that are emerging in 
the EU increase the costs of adopting GM products to possibly prohibitive levels.   
  
 
                                                 
21 An additional perspective on the spillover effects of EU-style regulations points to the problems, 
for developing countries, of adopting unnecessarily restrictive GM regulations. Paarlberg (2008), in 
particular, sees this as a very serious problem for African countries and argues that is could 
significantly undermine the potential role of biotechnology in helping solve the food problem of the 
very poor.  
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6. Conclusion 
Concerns about food procurement have always mattered, and still do. The global food 
balance equation, in the coming years, will be affected by the confluence of a number of 
secular trends. Population growth and income growth in developing countries are expected 
to sustain a strong global demand increase for agricultural output. The challenge of meeting 
such demand growth is compounded by the expansion of (subsidised) biofuel production in 
the United States and elsewhere, with its associated withdrawal of a large amount of land 
from food production, as well as the uncertainties of emerging global climate changes. 
Technological innovation, as for much of recent human history, will be needed to ensure 
that basic food needs are met in an efficient fashion. No single innovation can, of course, be 
expected to address all that. But recent advances, and current research, in the biosciences 
leave no doubt that biotechnology can play a critical role. 
A number of economic studies have shown that the extensive adoption of first-
generation GM crops in large agricultural producing regions has resulted in impressive 
productivity gains, as well as providing a number of environmental benefits, and the welfare 
gains attributable to GM innovations have been shared broadly among producers, 
consumers and innovators. Observers often lament that earlier GM products did not offer 
tangible benefits to consumers, but economists must disagree. The (ceteris paribus) price 
decrease that is induced by gains in production efficiency does benefit consumers, and even 
more so for low-income consumers whose food share of total expenditure is higher. 
Forgoing GM technology inevitably raises food prices. This is bad for society at large, and it 
is a particularly regressive policy that penalises less affluent citizens. The recent spikes in the 
prices of basic agricultural commodities, and what this means for the food security of the 
poor, might help foster a more balanced consideration of the positive impacts of agricultural 
productivity gains due to GM crops. 
First-generation GM technology has proven safe and effective, it has been 
enthusiastically adopted by farmers in some developed and developing countries and it is 
likely to have lasting effects on agriculture (Economist, 2008). Indeed, more is expected 
from agro-food biotechnology. Effective insect and weed control strategies embedded in the 
crops’ own genetic attributes are expected to become available for major crops (such as rice) 
so far not commercially affected, and GM improvements will tackle important abiotic 
stresses, such as the effects of drought conditions. In addition, second-generation GM crops 
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engineered for specific output attributes are expected to introduce novel food products that 
offer consumers nutritionally improved options that could have a variety of health benefits. 
But, as the economics of innovation would suggest, such advancements do not happen in a 
vacuum. A full harvest of biotechnology’s promises in the agro-food setting still requires a 
commitment to R&D, and, insofar as a critical amount of that effort needs to be carried out 
by the private sector, it needs an environment that welcomes the contributions of 
biotechnology and that promotes the adoption of better and safer products. 
Serious concerns about how that might play out in Europe are legitimate. GM crops, 
and products thereof, are highly regulated everywhere, but the stringency of EU regulations 
in this setting, and the vagaries of their implementation, represents an objective obstacle to 
GM product adoption, contributes to an increasing disharmony in international standards, 
which affects trade, and acts as a disincentive for sustained biotechnology R&D efforts in 
the agro-food sector. The unresolved problems that affect biotechnology regulation reflect, 
to a degree, a number of concerns that have dogged this technology from its early days. But 
as some initial fears and anxieties have been resolved by the accumulated evidence of science 
and rational analysis, the rigidities that in the meantime  have been built into the regulatory 
system might have a lasting detrimental effect. That this is having undesirable consequences 
is apparent. Whether the current structural obstacles can yet be effectively resolved so as to 
make the ‘European strategy’ a success remains to be seen.
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Table 1. Global trends and European strategy: Worldwide adoption of transgenic 
crops, 1996-2007 (millions of hectares) 
 
 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
USA 1.5 8.1 20.5 28.7 30.3 35.7 39.0 42.8 47.6 49.8 54.6 57.7 
Argentina 0.1 1.4 4.3 6.7 10.0 11.8 13.5 13.9 16.2 17.1 18.0 19.1 
Brazil … … … … … … … 3.0 5.0 9.4 11.5 15.0 
Canada 0.1 1.3 2.8 4.0 3.0 3.2 3.5 4.4 5.4 5.8 6.1 7.0 
India … … … … … … … … 0.5 1.3 3.8 6.2 
China … <0.1 <0.1 0.3 0.5 1.5 2.1 2.8 3.7 3.3 3.5 3.8 
other  … 0.1 0.1 0.2 0.4 0.4 0.6 0.8 2.6 3.3 4.5 5.5 
     EU … … 0.02 0.03 0.03 0.01 0.03 0.03 0.06 0.05 0.06 0.11 
World 1.7 11.0 27.8 39.9 44.2 52.6 58.7 67.7 81.0 90.0 102.0 114.3 
 
Source: International Service for the Acquisition of Agri-Biotech Applications.  EU data are 
from Gómez-Barbero and Rodríguez-Cerezo (2007) and GMO Compass website. 
 
